Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Safety Study of Palbociclib in Combination With Letrozole or Fulvestrant in African American Women With Hormone Receptor Positive HER2 Negative Advanced Breast Cancer

NCT02692755 is registered in ClinicalTrials.gov with Georgetown University as lead sponsor.

NCT NCT02692755
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02692755 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Safety Study of Palbociclib in Combination With Letrozole or Fulvestrant in African American Women With Hormone Receptor Positive HER2 Negative Advanced Breast Cancer
Lead sponsor
Georgetown University
Phase
Phase 2/3
Overall status
Completed
Start date
September 30, 2016
Completion date
March 23, 2021
Enrollment
35 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

hormone receptor positive her-2 negative breast cancer